Abstract:Importance Lipoprotein(a) (Lp[a]) is a causal risk factor for cardiovascular disease; however, long-term effects on coronary atherosclerotic plaque phenotype, high-risk plaque formation, and pericoronary adipose tissue inflammation remain unknown. Objective To investigate the association of Lp(a) levels with long-term coronary artery plaque progression, high-risk plaque, and pericoronary adipose tissue inflammation. Design, Setting, and Participants This single-center prospective cohort study included 299 patients with suspected coronary artery disease (CAD) who underwent per-protocol repeated coronary computed tomography angiography (CCTA) imaging with an interscan interval of 10 years. Thirty-two patients were excluded because of coronary artery bypass grafting, resulting in a study population of 267 patients. Data for this study were collected from October 2008 to October 2022 and analyzed from March 2023 to March 2024. Exposures The median scan interval was 10.2 years. Lp(a) was measured at follow-up using an isoform-insensitive assay. CCTA scans were analyzed with a previously validated artificial intelligence–based algorithm (atherosclerosis imaging-quantitative computed tomography). Main Outcome and Measures The association between Lp(a) and change in percent plaque volumes was investigated in linear mixed-effects models adjusted for clinical risk factors. Secondary outcomes were presence of low-density plaque and presence of increased pericoronary adipose tissue attenuation at baseline and follow-up CCTA imaging. Results The 267 included patients had a mean age of 57.1 (SD, 7.3) years and 153 were male (57%). Patients with Lp(a) levels of 125 nmol/L or higher had twice as high percent atheroma volume (6.9% vs 3.0%; P = .01) compared with patients with Lp(a) levels less than 125 nmol/L. Adjusted for other risk factors, every doubling of Lp(a) resulted in an additional 0.32% (95% CI, 0.04-0.60) increment in percent atheroma volume during the 10 years of follow-up. Every doubling of Lp(a) resulted in an odds ratio of 1.23 (95% CI, 1.00-1.51) and 1.21 (95% CI, 1.01-1.45) for the presence of low-density plaque at baseline and follow-up, respectively. Patients with higher Lp(a) levels had increased pericoronary adipose tissue attenuation around both the right circumflex artery and left anterior descending at baseline and follow-up. Conclusions and Relevance In this long-term prospective serial CCTA imaging study, higher Lp(a) levels were associated with increased progression of coronary plaque burden and increased presence of low-density noncalcified plaque and pericoronary adipose tissue inflammation. These data suggest an impact of elevated Lp(a) levels on coronary atherogenesis of high-risk, inflammatory, rupture-prone plaques over the long term.

Lipoprotein (a) is Related to In-Stent Neoatherosclerosis Incidence Rate and Plaque Vulnerability: Optical Coherence Tomography Study

Naturally Occurring Atherosclerosis Progression and In-stent Restenosis: Exploring Histomorphologic Associations Using Optical Coherence Tomography.

Association of Lipoprotein (a) With Coronary-Computed Tomography Angiography–Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes

Association Between the Neutrophil-to-Lymphocyte Ratio and in-Stent Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography Study

Correlation between lipoprotein(a) and recurrent ischemic events post-cerebral vascular stent implantation

Association Between Serum Uric Acid Levels and Neoatherosclerosis

Correlation of Lipoprotein (a) with Clinical Stability and Severity of Coronary Artery Lesions in Patients with Coronary Artery Disease

Effect of Devated Plasma Lipoprotein (a) on Restenosis after Stent Implantation

The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study

Impact of Serum Lipoprotein (A) Level on Coronary Artery Calcification: An Intravascular Ultrasound Study

Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy

Systemic immune inflammation index is associated with in-stent neoatherosclerosis and plaque vulnerability: An optical coherence tomography study

Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction

Lipoprotein (a) concentration as a risk factor for ischaemic stroke and its subtypes

Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement.

Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation

Abstract 15340: Association of Serum Lipoprotein (a) Levels and Lipid Burden by Near Infrared Spectroscopy in Intermediate Coronary Artery Disease

The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients

Lipoprotein(a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure

ASSOCIATION BETWEEN THE ATHEROGENIC INDEX OF PLASMA AND ADVERSE LONG-TERM PROGNOSIS IN PATIENTS DIAGNOSED WITH NON-ST ELEVATION ACUTE CORONARY SYNDROME

Association between Lipoprotein (A) and In-Hospital Outcomes in Patients with Acute ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention